eriodictyol has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbas, G; Ashraf, S; Choudhary, MI; Hafizur, RM; Hameed, A; Hussain, N; Khan, F; Raza, SA; Rehman, M; Ul-Haq, Z | 1 |
| Bucolo, C; Drago, F; Leggio, GM; Salomone, S | 1 |
2 other study(ies) available for eriodictyol and Alloxan Diabetes
| Article | Year |
|---|---|
Eriodictyol stimulates insulin secretion through cAMP/PKA signaling pathway in mice islets.
Topics: Animals; Blood Glucose; Calcium Channels; Cell Survival; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Experimental; Flavanones; Insulin; Insulin Secretion; Intracellular Space; Islets of Langerhans; Mice; Rats; Signal Transduction | 2018 |
Eriodictyol prevents early retinal and plasma abnormalities in streptozotocin-induced diabetic rats.
Topics: Animals; Antioxidants; Blood-Retinal Barrier; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Dose-Response Relationship, Drug; Flavanones; Lipid Peroxidation; Lipid Peroxides; Male; Molecular Structure; Oxidative Stress; Rats; Rats, Sprague-Dawley; Retina | 2012 |